Physician profile

John J Hennessey

Internal Medicine · Gales Ferry, CT

NPI 1215916564

$9,512.61

in general payments reported to CMS, 2019-2025

40 companies · $1,398 in 2025

The $1,398 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,262.58
Education$8.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $1,943.91 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Astrazeneca Pharmaceuticals LP $1,067.96 2019-2025 Airsupra, Farxiga, Breztri
Boehringer Ingelheim Pharmaceuticals, INC. $1,034.54 2019-2025 Jardiance, Tradjenta
Novo Nordisk INC $853.96 2019-2025 Ozempic, Rybelsus, Wegovy
Amgen INC. $521.02 2019-2025 Evenity, Prolia, Otezla
Astellas Pharma US INC $484.34 2019-2025 Veozah, Myrbetriq
Merck Sharp & Dohme LLC $325.48 2019-2025 Gardasil 9, Belsomra, Gardasil
Janssen Pharmaceuticals, INC $319.21 2019-2022
Pfizer INC. $312.36 2019-2025
Lilly USA, LLC $302.03 2019-2025 Mounjaro, Zepbound, Trulicity
Abbvie INC. $278.90 2019-2025
Allergan, INC. $276.18 2019
E.R. Squibb & Sons, L.L.C. $214.41 2019-2024 Eliquis
Stryker Corporation $145.91 2019
Sunovion Pharmaceuticals INC. $137.14 2021-2022
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Phathom Pharmaceuticals, INC. $131.04 2024-2025 Voquezna
Novartis Pharmaceuticals Corporation $122.78 2019-2022
Bayer Healthcare Pharmaceuticals INC. $102.18 2021-2025
Sumitomo Pharma America, INC. $98.09 2023-2024 Gemtesa
Otsuka America Pharmaceutical, INC. $85.88 2023-2025 Rexulti
Exact Sciences Corporation $81.33 2023-2025 Cologuard Collection Kit
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $76.03 2020-2025 Xifaxan
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $64.79 2025 Caplyta
Inspire Medical Systems, INC. $55.01 2025 Inspire
Eisai INC. $53.70 2021
Biohaven Pharmaceutical Holding Company LTD. $46.88 2022
Vanda Pharmaceuticals INC. $40.60 2024-2025 Fanapt, Ponvory
Hologic Sales and Service, LLC $39.59 2021-2022
Seqirus USA INC $38.30 2020-2022
Baxter Healthcare $32.94 2025 Hillrom - Carnation Ambulatory Monitor
Lundbeck LLC $32.39 2025 Rexulti
Amneal Pharmaceuticals LLC $32.03 2024-2025 Unithroid
Bausch Health US, LLC $28.77 2023-2024 Aplenzin, Wellbutrin
Alk-Abello, INC $27.64 2025 Neffy
Insightec,INC $23.43 2024 Exablate
Lucid Diagnostics INC. $18.88 2024
Amarin Pharma, INC. $17.38 2019
Boston Scientific Corporation $16.59 2025 Watchman Access System
Shire North American Group INC $15.37 2019
Echosens North America, INC. $13.64 2025 Fibroscan

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John J Hennessey

$9,512.61

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,398 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/145321/john-j-hennessey

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.